Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.

[1]  D. Postma,et al.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease , 2005, Thorax.

[2]  G. Mancini,et al.  Angiotensin II type 1 receptor blocker inhibits pulmonary injury. , 2005, Clinical and investigative medicine. Medecine clinique et experimentale.

[3]  D. Grigoryev,et al.  Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[4]  G. Mancini.  The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers. , 2005, The Canadian journal of cardiology.

[5]  James M Brophy,et al.  The Risk for Myocardial Infarction With Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults , 2005, Annals of internal medicine.

[6]  J. Nick,et al.  A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. , 2005, American journal of respiratory and critical care medicine.

[7]  P. Barnes,et al.  Prospects for new drugs for chronic obstructive pulmonary disease , 2004, The Lancet.

[8]  S. Rennard.  Treatment of stable chronic obstructive pulmonary disease , 2004, The Lancet.

[9]  S. Kimmel,et al.  Association between pulmonary fibrosis and coronary artery disease. , 2004, Archives of internal medicine.

[10]  S. Abe,et al.  Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist , 2003, Thorax.

[11]  J. Brophy,et al.  The use of cholesterol-lowering medications after coronary revascularization. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  Samy Suissa,et al.  The nested case-control study in cardiology. , 2003, American heart journal.

[13]  R. Johns,et al.  Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. , 2003, American journal of physiology. Heart and circulatory physiology.

[14]  N. Benowitz.  Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. , 2003, Progress in cardiovascular diseases.

[15]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[16]  B. Uhal,et al.  Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. , 2003, American Journal of Physiology - Lung cellular and Molecular Physiology.

[17]  G. Filippatos,et al.  Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. , 2003, Pharmacology & toxicology.

[18]  T. Assimes,et al.  Inhaled short acting β agonist use in COPD and the risk of acute myocardial infarction , 2003, Thorax.

[19]  B. Uhal,et al.  Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[20]  J. Hogg,et al.  Particulate air pollution induces progression of atherosclerosis. , 2002, Journal of the American College of Cardiology.

[21]  R. Burnett,et al.  Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. , 2002, JAMA.

[22]  F. Candan,et al.  Captopril inhibits the pulmonary toxicity of paraquat in rats , 2001, Human & experimental toxicology.

[23]  D. Dockery,et al.  Increased Particulate Air Pollution and the Triggering of Myocardial Infarction , 2001, Circulation.

[24]  J. Sarnat,et al.  Fine particulate air pollution and mortality in 20 U.S. cities. , 2001, The New England journal of medicine.

[25]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[26]  Christine Jenkins,et al.  GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY , 2001 .

[27]  F. Dominici,et al.  Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. , 2000, The New England journal of medicine.

[28]  W Winkelstein,et al.  Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. , 2000, Chest.

[29]  G. Laurent,et al.  Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. , 2000, American journal of respiratory and critical care medicine.

[30]  H. Katus,et al.  Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. , 2000, Circulation.

[31]  J. M. Taylor,et al.  Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. , 2000, International journal of radiation biology.

[32]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[33]  D. Mikhailidis,et al.  Cigarette smoking and cardiovascular disease , 1995, Journal of the Royal Society of Health.

[34]  A. Molteni,et al.  Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. , 1992, International journal of radiation oncology, biology, physics.

[35]  A. Siegelaub,et al.  Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.